Frontiers in Immunology (Dec 2021)
Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status
- Shaomin Gong,
- Shaomin Gong,
- Shaomin Gong,
- Shaomin Gong,
- Shaomin Gong,
- Shi Jin,
- Shi Jin,
- Shi Jin,
- Shi Jin,
- Shi Jin,
- Yang Li,
- Yang Li,
- Yang Li,
- Yang Li,
- Yang Li,
- Wuhua Jiang,
- Wuhua Jiang,
- Wuhua Jiang,
- Wuhua Jiang,
- Wuhua Jiang,
- Zhen Zhang,
- Zhen Zhang,
- Zhen Zhang,
- Zhen Zhang,
- Zhen Zhang,
- Ziyan Shen,
- Ziyan Shen,
- Ziyan Shen,
- Ziyan Shen,
- Ziyan Shen,
- Jialin Wang,
- Jialin Wang,
- Jialin Wang,
- Jialin Wang,
- Jialin Wang,
- Huili Zhou,
- Xiao Liu,
- Xialian Xu,
- Xialian Xu,
- Xialian Xu,
- Xialian Xu,
- Xialian Xu,
- Xiaoqiang Ding,
- Xiaoqiang Ding,
- Xiaoqiang Ding,
- Xiaoqiang Ding,
- Xiaoqiang Ding,
- Yiqin Shi,
- Yiqin Shi,
- Yiqin Shi,
- Yiqin Shi,
- Yiqin Shi,
- Hong Liu,
- Hong Liu,
- Hong Liu,
- Hong Liu,
- Hong Liu
Affiliations
- Shaomin Gong
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Shaomin Gong
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Shaomin Gong
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Shaomin Gong
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Shaomin Gong
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Shi Jin
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Shi Jin
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Shi Jin
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Shi Jin
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Shi Jin
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Yang Li
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Yang Li
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Yang Li
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Yang Li
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Yang Li
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Wuhua Jiang
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Wuhua Jiang
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Wuhua Jiang
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Wuhua Jiang
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Wuhua Jiang
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Zhen Zhang
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Zhen Zhang
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Zhen Zhang
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Zhen Zhang
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Zhen Zhang
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Ziyan Shen
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Ziyan Shen
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Ziyan Shen
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Ziyan Shen
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Ziyan Shen
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Jialin Wang
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Jialin Wang
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Jialin Wang
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Jialin Wang
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Jialin Wang
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Huili Zhou
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Xiao Liu
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Xialian Xu
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Xialian Xu
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Xialian Xu
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Xialian Xu
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Xialian Xu
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Xiaoqiang Ding
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Xiaoqiang Ding
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Xiaoqiang Ding
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Xiaoqiang Ding
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Xiaoqiang Ding
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Yiqin Shi
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Yiqin Shi
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Yiqin Shi
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Yiqin Shi
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Yiqin Shi
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- Hong Liu
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
- Hong Liu
- Shanghai Medical Center of Kidney Disease, Shanghai, China
- Hong Liu
- Shanghai Institute of Kidney and Dialysis, Shanghai, China
- Hong Liu
- Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China
- Hong Liu
- Hemodialysis Quality Control Center of Shanghai, Shanghai, China
- DOI
- https://doi.org/10.3389/fimmu.2021.769802
- Journal volume & issue
-
Vol. 12
Abstract
Noninvasive biomarkers of disease activity are needed to predict disease remission status in patients with IgA nephropathy (IgAN). Soluble CD163 (sCD163), shed by monocytes and macrophages, is a potential biomarker in diseases associated with excessive macrophage activation. We investigated the association of urinary sCD163 (u-sCD163) with histopathological activity and clinical manifestations in 349 patients with biopsy-diagnosed IgAN. U-sCD163 was measured via enzyme-linked immunosorbent assay. In patients with IgAN, higher u-sCD163 levels were associated with histological lesions of greater severity, as well as more proteinuria and poorer renal function. Additionally, u-sCD163 was correlated with infiltration of tubulointerstitial CD163+ macrophages. High u-sCD163 levels (>3.57 ng/mg Cr) were associated with a 2.66-fold greater risk for IgAN remission failure in adjusted analyses. Adding u-sCD163 levels to the model containing clinical data at biopsy and MEST-C score significantly improved the risk prediction of IgAN remission status (AUC 0.788). Together, our results suggest that u-sCD163 may be a useful noninvasive biomarker to evaluate disease severity and remission status of IgAN.
Keywords
